Loading your page…
Marketing-authorisation holder · Brazil
10 medicines in 1 country, as authorisation holder.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Every medicine in the registers under its name, current ones first.
10 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| anastrozol | Anastrozole | Brazil | Authorised | 2025 |
| cloridrato de erlotinibe | Erlotinib | Brazil | Authorised | 2025 |
| CLORIDRATO DE LIDOCAINA | Lidocaine | Brazil | Authorised | 2026 |
| DIXMABIO | Sugammadex | Brazil | Authorised | 2026 |
| EMNYRA | Teriflunomide | Brazil | Authorised | 2025 |
| ETORICOXIBE | Etoricoxib | Brazil | Authorised | 2025 |
| Ixobam | Apixaban | Brazil | Authorised | 2025 |
| lacosamida | Lacosamide | Brazil | Authorised | 2025 |
| LUNIERA | Vildagliptin | Brazil | Authorised | 2025 |
| rivaroxabana | Rivaroxaban | Brazil | Authorised | 2025 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Brazil | 10 | 10 | 0 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
ANVISA / CMED, consumer price table; embedded source date 2026-07-21 and retrieval date
Licence: Other (Public Domain)
Anvisa published factual open-data CSV https://dados.anvisa.gov.br/dados/CONSULTAS/PRODUTOS/TA_CONSULTA_MEDICAMENTOS.CSV, HTTP version Mon, 12 Oct 2026 11:45:25 GMT; acquired 12 October 2026; original source states and timestamps retained.
Licence: Brazil federal factual open data, consolidated Decreto 8777/2016 article 4; attribution and third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Ranked by their number of medicines.
